异基因造血干细胞移植治疗孤立性髓细胞肉瘤4例1
赵晔 1吴德沛 1孙爱宁 1仇惠英 1唐晓文 1马骁1
作者信息
- 1. 苏州大学附属第一医院215006; 江苏省血液研究所 卫生部血栓与止血重点实验室血液学协同创新中心
- 折叠
摘要
目的：：探讨应用异基因造血干细胞移植（allogeneic hematopoietic stem cell transplantation, allo- HSCT）治疗孤立性髓细胞肉瘤（myeloid sarcoma, MS）的安全性和有效性。方法：从临床表现、诊断、治疗等方面，回顾性分析了接受allo- HSCT的4例孤立性MS患者资料。结果：4例患者均以髓外肿块为首发表现，经局部肿块病理活检，免疫组化提示髓过氧化物酶均为阳性，部分CD68、溶菌酶、CD34阳性。患者接受了全身化疗，并行清髓性allo- HSCT。术后随访，1例因疾病进展死亡，3例存活。结论：allo- HSCT治疗孤立性MS是一种较安全的治疗手段，并能使患者获得更好的无病生存（disease- free survival, DFS）。
Abstract
Objective To evalute the safty and efficiency of allogeneic hematopoietic stem cell transplantation (allo- HSCT) in pri-mary myeloid sarcoma (MS). Methods The clinical manifestations, diagnosis, and treatment of 4 cases with primary MS treated with al-lo- HSCT were retrospectively analyzed. Results All of the 4 patients presented with extramedullary tumors as first symptom. Pathologi-cal biopsies were performed. Immuno- histological analysis showed that myeloperoxidase (MPO) were positive in all 4 cases, while CD68, lysozyme and CD34 were positive in some cases. After the chemotherapy, myeloablative allo- HSCT were administrated in these 4 patients. At present, 1 patient died because of the progression of the disease, while 3 patients survived. Conclusion Allo- HSCT in treating primary MS is safe, and can bring patients better disease- free survival (DFS).
关键词
异基因造血干细胞移植/髓细胞肉瘤Key words
myeloid sarcoma/allogeneic hematopoietic stem cell transplantation引用本文复制引用
基金项目
受江苏省科教兴卫工程-临床医学中心(ZX201102)
国家临床重点专科建设项目()
江苏省科教兴卫工程-临床医学中心(ZX201102)
出版年
2015
NETL
NSTL
万方数据